predominantly medium-vessel vasculitis
ORPHA: 1561434 Treatments Available
Overview
human disease
Available Treatments (4)
| Drug | Form | Status | Countries | Lead Time |
|---|---|---|---|---|
| tocilizumab Cold Chain | IV infusion 20mg/mL; subcutaneous injection 162mg/0.9mL | FDA Approved, EMA Approved | 10 | 7d |
| azathioprine | Oral tablets 25mg, 50mg, 75mg, 100mg | FDA Approved, EMA Approved | 10 | 3d |
| prednisolone | Oral tablets 5mg, 10mg, 20mg; oral solution 15mg/5mL | FDA Approved, EMA Approved | 8 | 2d |
| rituximab Orphan Cold Chain | IV infusion 10mg/mL (100mg/10mL, 500mg/50mL vials) | FDA Approved | 11 | 14d |
Classification & Codes
Orphanet Code
ORPHA:156143predominantly medium-vessel vasculitis
| Orphanet | ORPHA:156143 |
| Treatments | 4 drug(s) |
| Status | published |
Treatment Summary
Factual Authority
Last Updated3/20/2026
Clinical DataHPO · Orphanet
Drug DataFDA · EMA · CDSCO